| N-Octyl-2-Hydroxyethyl Sulfoxide |
Ferrichrome-iron receptor;Colicin I receptor;Outer membrane porin C | | |
| Oxyphenisatin |
| A06AB01 | |
| (2R)-2-({6-[benzyl(methyl)amino]-9-isopropyl-9H-purin-2-yl}amino)butan-1-ol |
Pyridoxal kinase | | |
| Blinatumomab |
B-lymphocyte antigen CD19;T-cell surface glycoprotein CD3 delta chain | L01XC19 | Indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). |
| Elosulfase alfa |
| A16AB12 | Vimizim is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). |
| Metreleptin |
Leptin receptor | | Metreleptin is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. |
| Dulaglutide |
Glucagon-like peptide 1 receptor | A10BX14 | Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. |
| Albiglutide |
Glucagon-like peptide 1 receptor | A10BX13 | Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. |
| Pembrolizumab |
Programmed cell death protein 1 | L01XC18 | Pembrolizumab is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of:
patients with unresectable or metastatic melanoma.
patients with metastatic NSCLC whose tumors have high PD-L1 expression [(Tumor Proportion Score (TPS) ≥50%)] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC.
patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.
patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. |
| Siltuximab |
Interleukin-6 | L04AC11 | Siltuximab is indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. Siltuximab did not bind to virally produced IL-6 in a nonclinical study and was therefore not studied in patients with MCD who are HIV or HHV-8 positive. |
| Nivolumab |
Programmed cell death protein 1 | L01XC17 | Nivolumab is indicated for the treatment of unresectable or metastatic melanoma for patients who no longer respond to treatment with other drugs. It is intended for use in patients who have been previously treated with ipilimumab and is used for melanoma patients after treatment with ipilimumab and a BRAF inhibitor in patients whose tumors express BRAF V600 gene mutations. Historically there have been very few effective treatments for advanced melanoma, which is why this product was approved under an FDA accelerated program to allow earlier patient access. |
| Vedolizumab |
Integrin alpha-4;Integrin beta-7 | L04AA33 | Vedolizumab is indicated for adult patients with moderately to severely active UC or CD who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids. |
| Secukinumab |
Interleukin-17A | L04AC10 | For the treatment of moderate to severe plaque psoriasis in patients that are candidates for systemic therapy or phototherapy. |
| Obinutuzumab |
B-lymphocyte antigen CD20 | L01XC15 | Obinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. |
| Certolizumab pegol |
Tumor necrosis factor | L04AB05 | Reducing signs and symptoms of Crohn's disease and treatment of moderately to severely active rheumatoid arthritis (RA). |
| Raxibacumab |
Protective antigen | J06BB18 | Raxibacumab is indicated for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate. |
| Teduglutide |
Glucagon-like peptide 2 receptor | A16AX08 | Treatment of short bowel syndrome (SBS), malabsorption associated with the removal of the intestine, in adults patients who are dependent on parenteral support. |
| Glucarpidase |
| V03AF09 | Used in patients on methotrexate treatment who have kidney dysfunction, and are experiencing an abnormally high plasma concentration of methotrexate (> 1 micromole per liter). |
| Ocriplasmin |
Fibronectin;Alpha-2-macroglobulin;Alpha-2-antiplasmin | S01XA22 | Ocriplasmin is a proteolytic enzyme indicated for the treatment for symptomatic vitreomacular adhesion. |
| Asparaginase Erwinia chrysanthemi |
| | Asparaginase Erwinia chryanthemi is for the treatment of patients with acute lymphoblastic leukemia (ALL) that have developed a hypersensitivity to Escherichia coli-derivied asparaginase. It is a component of a multi-agent chemotherpeutic regimen for the treatment of the aforementioned disease and is considered second- or third- line treatment in European and American protocols. |
